The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies | Zendy

John B. Buse | Zendy; Ralph A. DeFronzo | Zendy; Julio Rosenstock | Zendy; Terri Kim | Zendy; Colleen Burns | Zendy; Sharon Skare | Zendy; Alain Baron | Zendy; Mark Fineman | Zendy

Open Access

The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies

Author(s) -

John B. Buse,

Ralph A. DeFronzo,

Julio Rosenstock,

Terri Kim,

Colleen Burns,

Sharon Skare,

Alain Baron,

Mark Fineman

Publication year - 2015

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc15-0488

Subject(s) - metformin , medicine , placebo , glycemic , pharmacokinetics , crossover study , type 2 diabetes , adverse effect , bioavailability , tolerability , diabetes mellitus , cmax , randomized controlled trial , gastroenterology , pharmacology , endocrinology , insulin , alternative medicine , pathology

Delayed-release metformin (Met DR) is formulated to deliver the drug to the lower bowel to leverage the gut-based mechanisms of metformin action with lower plasma exposure. Met DR was assessed in two studies. Study 1 compared the bioavailability of single daily doses of Met DR to currently available immediate-release metformin (Met IR) and extended-release metformin (Met XR) in otherwise healthy volunteers. Study 2 assessed glycemic control in subjects with type 2 diabetes (T2DM) over 12 weeks.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research